companies / carislifesciences-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-18 json
| total_raised | 1,230,000,0001.2B | ○ |
|---|---|---|
| founded | 2018 | |
| hq | Irving, USA | |
| industry | unknown | |
| stage | series-b+ |
Caris MI Profile performs whole-exome and whole-transcriptome sequencing on tumor tissue, analyzing 23,000+ genes alongside protein expression data to build a molecular blueprint of a patient's cancer. It serves oncologists and cancer patients seeking personalized treatment guidance. The test combines DNA, RNA, and protein analysis with AI-predictive algorithms in a single tissue-based assay — a multi-omic profile most competitors split across separate workflows.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-04-01 | series-d+ | 168,000,000168.0M | null | ○ |
Nginx, WordPress 6.9.4, Yoast SEO 27.6, Google Tag Manager, WordPress Block Editor, WordPress Site Editor, WordPress VIP, PHP, MySQL
| fact | status | src |
|---|---|---|
| Series D+, $168.0M | attributed | ○ |
| existence | sourced | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-10-17provenance_existence: self-reported → sourced, WEB 2026-10-17 | provenance_existence | self-reported → sourced | WEB 2026-10-17 |
Records begin 2026-09-24. all_changes